Clinical Trials Logo
  1. Home
  2. Influenza A Virus Infection
  3. NCT00844155

Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir in the Intensive Care Unit

Influenza A Virus Infection Clinical Trial

Official title:
A Study of the Relative Oral Bioavailability of the Antiflu Medicine Oseltamivir (Tamiflu®) in Patients in the Intensive Care Unit

Clinical Trial Summary

This proposed pharmacokinetic study will test the hypothesis that in critically ill patients with respiratory failure requiring mechanical ventilation such as might be anticipated to be needed to treat patients with severe influenza pneumonia, oseltamivir administered enterally via nasogastric tube, with and without concomitant food or alimentation, will have similar oral bioavailability to that observed in ambulatory adults ill with influenza in whom oseltamivir therapy 75 mg BID is efficacious and well tolerated. Additionally, this experiment will test the hypothesis that increasing the dose (150 mg), with and without concomitant enteral feeding, will show a proportionate increase in bioavailability. Relative oral bioavailability will be assessed from plasma concentration vs. time over 12 hrs and urinary recovery of drug from 0 to 48 hrs after administration.

Clinical Trial Description

Not required ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00844155
Study type Interventional
Source University of Manitoba
Contact
Status Withdrawn
Phase N/A
Start date March 2009
Completion date July 2009
View Details
See also
  Status Clinical Trial Phase
Completed NCT02250274 - Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents Phase 4
Completed NCT01175122 - Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza Phase 1
Completed NCT00984451 - A Pilot Study for Collection of Anti-Influenza A Immune Plasma
Completed NCT00985582 - Antiviral Therapy for Influenza A H1N1 N/A
Completed NCT01459081 - Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China Phase 3
Completed NCT03651544 - The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac Phase 1
Completed NCT02572817 - Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A Phase 3
Completed NCT00491985 - Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children Phase 2
Completed NCT01146535 - Interferon Alpha Lozenges Plus Oseltamivir for Influenza Treatment Phase 2
Completed NCT00457509 - Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults Phase 1
Completed NCT01546506 - Confirmation of the Antiviral Effects of Midodrine Identified With a Gene Expression Signature-based Screening of Inluenza A Virus Infected Cells Phase 2
Completed NCT01136057 - Blood and Plasma Collection For Use in Future Clinical Trials